Executive summary
US Drug Patent 8,202,537 is a formulation-and-process style patent that claims a solid modified-release methylphenidate tablet built around methylphenidate–sulfonated styrene-divinylbenzene ion-exchange resin complexes and a cured, high-tensile, water-permeable, water-insoluble, non-ionic polymeric diffusion barrier coating. The claim set is heavily constrained by (i) the polymer/resin composition, (ii) coating polymer chemistry and curing parameters, and (iii) quantified ranges for coating plasticizer, elongation factor, polymer ratios, and tablet release suitability (≥12-hour profile). The scope is narrow enough that competing solid oral modified-release methylphenidate products can potentially design around by changing one or more of: the resin identity (sulfonated styrene/divinylbenzene), the barrier-coating chemistry (polyvinylacetate/polyvinylpyrrolidone + triacetin-type plasticizer via the stated coating approach), or the quantified coating morphology/performance parameters (elongation factor and cure conditions).
Detailed patent landscape for US Patent 8,202,537 (methylphenidate ion-exchange resin complex + diffusion barrier coating)
What is US Patent 8,202,537 claiming, and what is the core inventive concept?
Core claim architecture (Claim 1):
A solid modified-release methylphenidate tablet providing at least ~12-hour release for oral ingestion comprising compressed tablet excipients and a specific “methylphenidate particulate” system that includes two particulate populations:
- Modified-release methylphenidate component (A)
-
Single active drug: methylphenidate (explicitly allows dexmethylphenidate in dependent claims).
-
Particulate matrix comprising:
- methylphenidate–ion exchange resin complex (methylphenidate bound to a water-insoluble ion exchange resin)
- plus water insoluble polymer/copolymer or hydrophilic polymer present at ~3% to ~30% by weight based on the weight of the resin complex
-
The particulate matrix is passable through a #40 mesh screen (particle size constraint).
-
The ion exchange resin is defined as a sulfonated copolymer comprising styrene and divinylbenzene.
-
Cured, high tensile strength, water permeable, water insoluble, non-ionic polymeric diffusion barrier coating over the matrix.
- Barrier coating applied as an aqueous dispersion
- Comprises:
- polyvinylacetate (PVAc)
- a stabilizer
- an effective amount of plasticizer to enhance tensile strength
- The cured barrier coating is described as creating the modified release profile to methylphenidate in the resin-complex matrix.
- Particulate uncoated methylphenidate-ion exchange resin complex (B)
- Methylphenidate is the sole active drug bound to the same water-insoluble sulfonated styrene-divinylbenzene ion exchange resin.
- This uncoated portion is included alongside component (A) in the tablet.
Functional target: modified release with a ≥12-hour profile.
Business implication: to infringe independent claim 1, an accused product must embody the two-part particulate system (coated modified-release resin complex + uncoated resin complex) and the coating/resin chemistry plus multiple parameter constraints that later claims quantify.
What parts of claim 1 are the highest-value “gatekeepers” for infringement?
Claim 1 has multiple built-in bottlenecks. The most gatekeeping elements are:
- Resin identity constraint
- The ion exchange resin must be a sulfonated styrene-divinylbenzene copolymer (for both coated matrix (A) and uncoated complex (B)).
- Two-part particulate system
- Component (A): coated resin complex matrix
- Component (B): uncoated resin complex
If a competitor uses only one population or replaces the uncoated portion with a different functional particle strategy, claim 1 scope narrows.
- Coating chemistry constraint
- Coated component requires a cured diffusion barrier coating:
- polyvinylacetate polymer
- stabilizer
- plasticizer
- The coating must be applied as an aqueous dispersion and be cured to yield high tensile strength and a water permeable, water insoluble, non-ionic barrier.
- Particle size constraint
- Particulate matrix capable of passing through a #40 mesh screen.
- Tablet-level release requirement
- Tablet is “suitable for oral ingestion” and “provides at least about a 12 hour release profile.”
Net: the claim is not just “methylphenidate in a resin complex”; it requires a specific resin chemistry plus a PVAc-based cured barrier overlay, plus inclusion of an uncoated resin-complex fraction.
How do the dependent claims narrow the scope on resin particle shape and methylphenidate identity?
Claim 2 (shape): resin particle is irregularly shaped.
This can matter for infringement arguments where resin morphology is a measurable trait tied to manufacturing grade.
Claim 3 (drug identity): methylphenidate may be dexmethylphenidate in (A) and/or (B).
This expands coverage to formulations using dexmethylphenidate rather than racemic methylphenidate, while still tethering to the same resin complex and coating system.
What formulation ranges are explicitly claimed for the resin-matrix polymer (3% to 30%)?
Claim 4:
- The water insoluble polymer/copolymer/hydrophilic polymer in the particulate matrix is ~5% to ~20% by weight (based on methylphenidate-ion exchange resin complex defined in (i)).
This is narrower than Claim 1’s broader ~3% to ~30%.
Claim 6 and 7 (hydrophilic polymer species):
- Hydrophilic polymer may be included (Claim 6).
- Example hydrophilic polymer: polyvinylpyrrolidone (PVP) (Claim 7).
Claim 8 (coating dispersion solids and polymer ratios):
- aqueous based coating dispersion comprises about 30% solids including:
- PVAc and PVP in dry weight ratio 10:1
- includes an effective amount of surfactant
This constrains formulation composition of the coating dispersion that is then cured.
Claims 9–11 (PVAc + stabilizer system and example dispersion composition):
- Claim 10: the matrix comprises polyvinylacetate with a stabilizer comprising polyvinylpyrrolidone plus surfactant.
- Claim 11: provides an example dispersion composition (solids basis):
- PVAc ~27% w/w of solids
- PVP ~2.7% w/w of solids
- sodium lauryl sulfate ~0.3% w/w of solids
This is a concrete blueprint for a PVAc/PVP/surfactant coating formulation and is likely to be cited in doctrine-of-equivalents or specific device arguments.
What coating performance and mechanical constraints are claimed (elongation factor, plasticizer load)?
Claim 5 (elongation factor):
- cured barrier coating elongation factor between about 125% and 400%.
Claim 12 (plasticizer load):
- plasticizer comprises about 5% to 10% w/w of solids in the cured coating.
Claim 13 (plasticizer identity):
- plasticizer comprises triacetin.
Claim 14 (additional surfactant):
- barrier coating includes sodium lauryl sulfate.
Claim 15–17 (coating weight fraction inside the coated matrix):
- Claim 15: barrier coating comprises about 5% to 200% by weight of the matrix defined in (i).
- Claim 16: barrier coating comprises about 35% to 50% by weight of the matrix (narrower).
- Claim 17: barrier coating comprises about 30% to 45% by weight of the matrix.
Claim 18–20 (curing time and temperature):
- Claim 18: cured for about 4 to 16 hours
- Claim 19: cured for about 5 hours at 50°C to 65°C
- Claim 20: cured at about 60°C
Claim 21 (explicit 50% coating by weight):
- cured barrier coating comprises about 50% by weight of the matrix defined in (i).
Business implication: these dependent claims anchor to measurable mechanical and process parameters. Design-around risk is highest if competitors try to match release profile but do not use PVAc-based cured diffusion barrier coatings with similar mechanical performance and cure conditions, or if they swap plasticizer identity away from triacetin and/or alter surfactant.
How does claim scope handle the tablet composition beyond the resin-coated system?
Claim 22:
tablet further comprises a methylphenidate component not in a drug-ion exchange resin complex, in addition to the modified-release component (A) and uncoated complex (B).
This claim increases potential literal infringement pathways for products that include additional free drug. It also signals that the patent does not require the entire dose to be fully complexed.
What coating layer composition is explicitly claimed (PVAc/PVP/plasticizer percent ranges)?
Claim 23:
cured barrier coating comprises (based on weight of cured barrier coating layer):
- PVAc 70% w/w to 90% w/w
- PVP 5% w/w to 10% w/w
- plasticizer 2.5% w/w to 20% w/w
This is a direct chemistry-to-weight mapping and can be used in claim charts against accused formulations.
What is the practical scope of claim 24 (resin complex fraction in matrix)?
Claim 24:
cured barrier coating comprises about 25% to 35% by weight of the methylphenidate-ion exchange resin complex-matrix defined in (i).
This is another tether on the mass balance between resin complex matrix and barrier coating.
Claim-by-claim infringement map (what an accused product must have)
| Claim element |
Infringement gate |
How competitors can design around (scope reduction) |
| Modified-release tablet with ≥12-hour profile |
Product-level functional limitation |
Switch to non-resin-based release systems or different release kinetics, if this is truly measurable |
| Resin complex with sulfonated styrene-divinylbenzene |
High gate |
Use different ion exchange chemistry or non-sulfonated resin types |
| Coated component (A) over matrix with diffusion barrier |
High gate |
Replace PVAc-based diffusion barrier with different polymer class or non-cured barrier method |
| Coating applied as aqueous dispersion and cured to high tensile strength, water permeable and water insoluble, non-ionic |
High gate |
Use different coating polymer class, ionic character, or curing mechanism |
| PVAc + stabilizer (PVP) + plasticizer |
High gate |
Change polymer system; remove PVP stabilizer; change plasticizer class |
| Plasticizer identity triacetin |
Dependent gate |
Use different plasticizer (e.g., citrates without triacetin) to avoid Claim 13 |
| Surfactant sodium lauryl sulfate |
Dependent gate |
Replace surfactant system |
| Elongation factor 125% to 400% |
Dependent gate |
Alter coating mechanical properties via polymer/plasticizer changes |
| Cure time/temp (4-16 hours; 5 hours at 50-65°C; 60°C) |
Dependent gate |
Change cure conditions (though doctrine-of-equivalents risk remains) |
| Two particulate populations: coated modified-release resin complex + uncoated resin complex |
High gate |
Omit uncoated portion or use different particle population design |
Usability of this patent in licensing and litigation: strongest and weakest hooks
Strongest hooks (highest leverage):
- Resin identity: sulfonated styrene-divinylbenzene ion exchange resin complex.
- PVAc-based cured diffusion barrier overlay applied from aqueous dispersion, with specified polymer/stabilizer/plasticizer framework.
- Quantified mechanical/process parameters in dependent claims (elongation factor, cure time/temp, plasticizer load, coating ratios).
Potential weak hooks (more litigable/contested):
- The functional “at least about 12 hour release profile” limitation is susceptible to argument over measurement method and equivalence of release profiles.
- Some dependent constraints (e.g., broad ranges like 5% to 200% barrier coating by weight) may overlap with a wide set of formulations, reducing their discriminating power.
What patent landscape can be derived from the claim content alone?
The provided material includes only the claims text for US 8,202,537 and does not include prosecution history, cited prior art, inventor/jurisdiction data, or other family members. Based on claims alone, the relevant landscape clusters are:
- Ion exchange resin–based modified release methylphenidate
- The patent’s novelty posture likely targets resin complexation plus particle sizing and controlled barrier coating.
- Polymeric diffusion barrier coatings on drug-resin complexes
- PVAc-based, cured, water-permeable and water-insoluble diffusion barrier layers with triacetin-type plasticization and PVP stabilizer.
- Tablet blending architecture
- inclusion of both coated and uncoated resin complex particulate fractions, with possible extra free methylphenidate outside resin complexes.
For competitive intelligence, infringement risk should be evaluated at the material-system level (resin chemistry + coating polymer/plasticizer/surfactant + cure process), not only at the marketing-level “12-hour methylphenidate.”
Key Takeaways
- US 8,202,537 claims a solid modified-release methylphenidate tablet built from methylphenidate–sulfonated styrene-divinylbenzene ion exchange resin complexes, combining coated modified-release particles (A) and uncoated complex particles (B).
- The patent’s practical infringement scope is governed by the specific resin identity and the cured PVAc-based diffusion barrier coating (aqueous dispersion, stabilized with PVP, plasticized with triacetin in dependent claims).
- Dependent claims add measurable constraints: elongation factor (125%–400%), plasticizer 5%–10% solids, surfactant (sodium lauryl sulfate), and curing time/temperature (including 5 hours at 50–65°C or 60°C).
- Design-around efforts should focus on changing at least one of the claim-defining material systems (resin chemistry and/or diffusion barrier polymer/plasticizer/cure approach) rather than only tweaking dose or general release profile.
FAQs
1) What resin changes most directly avoid US 8,202,537?
Avoid ion exchange resins that are not sulfonated styrene-divinylbenzene copolymers, since both coated (A) and uncoated (B) complex requirements tie to that structure.
2) Can a competitor infringe if the tablet achieves 12-hour release but uses a non-PVAc diffusion barrier?
The independent claim requires a cured, high tensile strength, water permeable, water insoluble, non-ionic polymeric diffusion barrier coating with polyvinylacetate as the polymer core; switching polymer systems can materially narrow infringement.
3) Does US 8,202,537 require triacetin?
Triacetin is in dependent Claim 13. Literal infringement of claim sets that include Claim 13 requires triacetin as the plasticizer; changing plasticizer can reduce risk.
4) What parameters are most useful for claim charts?
Use coating composition (PVAc/PVP ratios, surfactant), plasticizer loading, elongation factor, and cure time/temperature, plus whether the product contains both coated and uncoated resin complex particulate populations.
5) Does the patent cover dexmethylphenidate formulations?
Yes. Claim 3 expressly allows dexmethylphenidate in component (A) and/or (B), assuming the same resin complex and diffusion barrier system.
References
- User-provided claim text for US Patent 8,202,537 (claims 1–24).
